MIRA
MIRA Pharmaceuticals, Inc. (MIRA) 10Y Growth Potential Analysis (2026)
Overall Score
Business Quality
MIRA shows no meaningful revenue or margin profile in TTM data, with gross, operating, EBITDA, and net margins all at 0% and asset turnover at 0.
Return metrics are deeply negative, including ROA of -1.16%, ROE of -1.07%, and ROIC of -1.15%, indicating the business is not generating economic returns.
The company’s current ratio is extremely high at 200.1x, but this appears to reflect a very small balance sheet rather than durable operating strength.
Financial Strength
Liquidity appears strong on paper with a current ratio of 200.1x and cash ratio of 88.4x, supported by positive working capital of $8.1M.
Debt metrics are minimal in the reported data, with debt-to-assets and debt-to-equity both at 0, and net debt to EBITDA at 0.38x.
Despite liquidity, solvency is weak with a negative solvency ratio of -232.2 and operating cash flow remains negative at -$0.11 per share.
Growth Trends
TTM growth indicators are not supportive of a growth thesis, as revenue per share is 0 and profitability margins remain at 0%.
There is no evidence of scaling efficiency in the reported metrics, with operating cycle, cash conversion cycle, and turnover ratios all at 0.
No recent news was provided to indicate product, customer, or market-driven growth acceleration.
Valuation
Traditional valuation ratios are difficult to interpret because sales and cash flow metrics are distorted or negative, but price-to-book is 4.37x and price-to-fair-value is 4.37x.
Price-to-free-cash-flow is negative at -7.70x, reflecting negative free cash flow generation.
The stock appears inexpensive on some earnings-based measures, but those are not meaningful given negative earnings and operating losses.
Risk Profile
The main risk is persistent unprofitability, with negative margins, negative cash flow, and negative returns on capital across the board.
The balance sheet is small and fragile despite high liquidity ratios, which may make the company sensitive to operating setbacks.
No recent news was provided, so there are no new event-driven risks or catalysts to incorporate this month.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on MIRA Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

